620 related articles for article (PubMed ID: 22436957)
21. Marrow Mesenchymal Stem Cells Effectively Reduce Histologic Changes in a Rat Model of Chronic Renal Allograft Rejection.
Yu P; Wang Z; Liu Y; Xiao Z; Guo Y; Li M; Zhao M
Transplant Proc; 2017 Nov; 49(9):2194-2203. PubMed ID: 29149982
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study.
Wei Y; Chen X; Zhang H; Su Q; Peng Y; Fu Q; Li J; Gao Y; Li X; Yang S; Ye Q; Huang H; Deng R; Li G; Xu B; Wu C; Wang J; Zhang X; Su X; Liu L; Xiang AP; Wang C
Front Immunol; 2021; 12():662441. PubMed ID: 34248942
[TBL] [Abstract][Full Text] [Related]
23. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
25. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients.
Locke JE; James NT; Mannon RB; Mehta SG; Pappas PG; Baddley JW; Desai NM; Montgomery RA; Segev DL
Transplantation; 2014 Feb; 97(4):446-50. PubMed ID: 24162248
[TBL] [Abstract][Full Text] [Related]
27. Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis.
Zhao L; Hu C; Han F; Chen D; Cheng J; Wu J; Peng W; Chen J
Stem Cell Res Ther; 2021 Mar; 12(1):158. PubMed ID: 33648596
[TBL] [Abstract][Full Text] [Related]
28. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
29. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.
Yong K; Nguyen HD; Hii L; Chan DT; Boudville N; Messineo A; Lim EM; Dogra GK; Lim WH
Am J Hypertens; 2013 Jul; 26(7):843-9. PubMed ID: 23443728
[TBL] [Abstract][Full Text] [Related]
30. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
[TBL] [Abstract][Full Text] [Related]
31. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.
Reinders ME; de Fijter JW; Roelofs H; Bajema IM; de Vries DK; Schaapherder AF; Claas FH; van Miert PP; Roelen DL; van Kooten C; Fibbe WE; Rabelink TJ
Stem Cells Transl Med; 2013 Feb; 2(2):107-11. PubMed ID: 23349326
[TBL] [Abstract][Full Text] [Related]
32. Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation - single center experience.
Vanikar AV; Trivedi HL; Kumar A; Gopal SC; Patel HV; Gumber MR; Kute VB; Shah PR; Dave SD
Ren Fail; 2014 Oct; 36(9):1376-84. PubMed ID: 25246338
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
[TBL] [Abstract][Full Text] [Related]
34. Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus.
Ali H; Sharma A; Halawa A
Am J Nephrol; 2020; 51(5):366-372. PubMed ID: 32268334
[TBL] [Abstract][Full Text] [Related]
35. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
Woodle ES; First MR; Pirsch J; Shihab F; Gaber AO; Van Veldhuisen P;
Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
37. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
38. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
39. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
Moore J; Middleton L; Cockwell P; Adu D; Ball S; Little MA; Ready A; Wheatley K; Borrows R
Transplantation; 2009 Feb; 87(4):591-605. PubMed ID: 19307799
[TBL] [Abstract][Full Text] [Related]
40. Anti-IL-2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation.
Del Bello A; Divard G; Belliere J; Congy-Jolivet N; Lanfranco L; Ricard R; Delas A; Colombat M; Esposito L; Hebral AL; Cointault O; Lefaucheur C; Loupy A; Kamar N
Clin Transplant; 2019 Oct; 33(10):e13681. PubMed ID: 31369170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
